October 14, 2022

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Europe's high mortality linked to antimicrobial resistance needs action now

Age-standardized mortality rate associated with and attributable to AMR in relation to the status of NAPs for the countries in the WHO European region. Rates per 100,000 person-years associated with AMR are colored according to NAP status, while rates attributable to AMR are gray. The category “no NAP” also includes countries that did not provide data about its status. NAP data was acquired from the 2020–21 Country Self-assessment Survey responses. Estimates were aggregated across drugs, accounting for the co-occurrence of resistance to multiple drugs. AMR=antimicrobial resistance. NAP=national AMR action plan. Credit: The Lancet Global Health (2022). DOI: 10.1016/S2468-2667(22)00225-0
× close
Age-standardized mortality rate associated with and attributable to AMR in relation to the status of NAPs for the countries in the WHO European region. Rates per 100,000 person-years associated with AMR are colored according to NAP status, while rates attributable to AMR are gray. The category “no NAP” also includes countries that did not provide data about its status. NAP data was acquired from the 2020–21 Country Self-assessment Survey responses. Estimates were aggregated across drugs, accounting for the co-occurrence of resistance to multiple drugs. AMR=antimicrobial resistance. NAP=national AMR action plan. Credit: The Lancet Global Health (2022). DOI: 10.1016/S2468-2667(22)00225-0

The latest and most comprehensive analysis of antimicrobial resistance (AMR) and its impact in the entire WHO European Region (53 countries) was published in a paper today in The Lancet Public Health. Researchers at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington's School of Medicine, Oxford Center for Global Health Research, Center for Tropical Medicine and Global Health, and other collaborators analyzed 23 bacterial pathogens and 88 pathogen-drug combinations to release the following findings:

In general, countries with national actions plans had lower rates of AMR burden, but further efforts are needed. Some of those strategies include better monitoring, improving hygiene and sanitation, expanding access to vaccines, and developing new treatments.

This is the first country-level analysis following the paper on the global burden of AMR published in January in The Lancet. More country-level estimates are to follow.

AMR will be a topic of discussion at the World Health Summit (WHS) taking place in Berlin, Germany Oct. 16–18. IHME Professor Dr. Mohsen Naghavi will address the global impact at the WHS on Tuesday, Oct. 18, 2022 at 11 a.m. CEST / 5 a.m. EDT.

More information: The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis, The Lancet Public Health (2022). DOI: 10.1016/S2468-2667(22)00225-0, www.thelancet.com/journals/lan … (22)00225-0/fulltext

Journal information: The Lancet Public Health , The Lancet Global Health , The Lancet

Load comments (0)